{"title":"血管紧张素受体阻滞剂对6 - 18岁儿童高血压患者的疗效和安全性:一项系统综述。","authors":"Sahar Bassiri, Elham Bakhtiari, Nafise Ghaffarian, Nasrin Moazzen, Yalda Ravanshad, Anoush Azarfar","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Angiotensin receptor blockers (ARBs) are commonly prescribed in pediatric hypertension because of the fundamental role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertension. We, therefore, aimed to systematically review articles that investigated efficacy and safety of ARB agents in the pediatric population aged over six years. To do so, the databases of Web of Science, PubMed/MEDLINE, and Scopus were searched to conduct a systematic review by using the following keywords: (\"angiotensin receptor blocker\" OR \"valsartan\" OR \"losartan\") AND (\"pediatric\" OR \"children\" OR \"child\") AND (\"high blood pressure\" OR \"hypertension\"). Finally, 12 studies were included in our review, and we found that almost all of them supported the effectiveness and tolerability of different ARB agents. Candesartan cilexetil lowered blood pressure (BP), with a 9 mmHg decline in both systolic and diastolic BP, and proteinuria after four months of treatment. Valsartan and Losartan similarly were shown to be effective in lowering BP in a dose-dependent manner. Headache, dizziness, upper respiratory infection, and cough were the most reported side effects. However, almost all reviewed studies indicated that the safety profile was satisfactory. In conclusion, ARBs are beneficial and well-tolerated antihypertensive medications. DOI: 10.52547/ijkd.7228.</p>","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"17 3","pages":"117-125"},"PeriodicalIF":0.8000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Angiotensin Receptor Blockers in Pediatric Patients (Aged 6 to 18) with Hypertension: A Systematic Review.\",\"authors\":\"Sahar Bassiri, Elham Bakhtiari, Nafise Ghaffarian, Nasrin Moazzen, Yalda Ravanshad, Anoush Azarfar\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Angiotensin receptor blockers (ARBs) are commonly prescribed in pediatric hypertension because of the fundamental role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertension. We, therefore, aimed to systematically review articles that investigated efficacy and safety of ARB agents in the pediatric population aged over six years. To do so, the databases of Web of Science, PubMed/MEDLINE, and Scopus were searched to conduct a systematic review by using the following keywords: (\\\"angiotensin receptor blocker\\\" OR \\\"valsartan\\\" OR \\\"losartan\\\") AND (\\\"pediatric\\\" OR \\\"children\\\" OR \\\"child\\\") AND (\\\"high blood pressure\\\" OR \\\"hypertension\\\"). Finally, 12 studies were included in our review, and we found that almost all of them supported the effectiveness and tolerability of different ARB agents. Candesartan cilexetil lowered blood pressure (BP), with a 9 mmHg decline in both systolic and diastolic BP, and proteinuria after four months of treatment. Valsartan and Losartan similarly were shown to be effective in lowering BP in a dose-dependent manner. Headache, dizziness, upper respiratory infection, and cough were the most reported side effects. However, almost all reviewed studies indicated that the safety profile was satisfactory. In conclusion, ARBs are beneficial and well-tolerated antihypertensive medications. DOI: 10.52547/ijkd.7228.</p>\",\"PeriodicalId\":14610,\"journal\":{\"name\":\"Iranian journal of kidney diseases\",\"volume\":\"17 3\",\"pages\":\"117-125\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian journal of kidney diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of kidney diseases","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
由于肾素-血管紧张素-醛固酮系统在高血压发病机制中的基础性作用,血管紧张素受体阻滞剂(ARBs)常用于小儿高血压。因此,我们旨在系统地回顾研究ARB药物在6岁以上儿童人群中的有效性和安全性的文章。为此,检索Web of Science、PubMed/MEDLINE和Scopus数据库,使用以下关键词(“血管紧张素受体阻阻剂”或“缬沙坦”或“氯沙坦”)和(“儿科”或“儿童”或“儿童”)和(“高血压”或“高血压”)进行系统评价。最后,我们的综述纳入了12项研究,我们发现几乎所有研究都支持不同ARB药物的有效性和耐受性。坎地沙坦西列地尔降低血压(BP),收缩压和舒张压均下降9 mmHg,治疗4个月后蛋白尿。缬沙坦和氯沙坦同样显示出以剂量依赖的方式有效降低血压。头痛、头晕、上呼吸道感染和咳嗽是报告最多的副作用。然而,几乎所有的审查研究表明,安全性是令人满意的。总之,arb是有益且耐受性良好的抗高血压药物。DOI: 10.52547 / ijkd.7228。
Efficacy and Safety of Angiotensin Receptor Blockers in Pediatric Patients (Aged 6 to 18) with Hypertension: A Systematic Review.
Angiotensin receptor blockers (ARBs) are commonly prescribed in pediatric hypertension because of the fundamental role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertension. We, therefore, aimed to systematically review articles that investigated efficacy and safety of ARB agents in the pediatric population aged over six years. To do so, the databases of Web of Science, PubMed/MEDLINE, and Scopus were searched to conduct a systematic review by using the following keywords: ("angiotensin receptor blocker" OR "valsartan" OR "losartan") AND ("pediatric" OR "children" OR "child") AND ("high blood pressure" OR "hypertension"). Finally, 12 studies were included in our review, and we found that almost all of them supported the effectiveness and tolerability of different ARB agents. Candesartan cilexetil lowered blood pressure (BP), with a 9 mmHg decline in both systolic and diastolic BP, and proteinuria after four months of treatment. Valsartan and Losartan similarly were shown to be effective in lowering BP in a dose-dependent manner. Headache, dizziness, upper respiratory infection, and cough were the most reported side effects. However, almost all reviewed studies indicated that the safety profile was satisfactory. In conclusion, ARBs are beneficial and well-tolerated antihypertensive medications. DOI: 10.52547/ijkd.7228.
期刊介绍:
The Iranian Journal of Kidney Diseases (IJKD), a peer-reviewed journal in English, is the official publication of the Iranian Society of Nephrology. The aim of the IJKD is the worldwide reflection of the knowledge produced by the scientists and clinicians in nephrology. Published quarterly, the IJKD provides a new platform for advancement of the field. The journal’s objective is to serve as a focal point for debates and exchange of knowledge and experience among researchers in a global context. Original papers, case reports, and invited reviews on all aspects of the kidney diseases, hypertension, dialysis, and transplantation will be covered by the IJKD. Research on the basic science, clinical practice, and socio-economics of renal health are all welcomed by the editors of the journal.